

The U.S. government does not review or approve the safety and science of all studies listed on this website.

Read our full [disclaimer](#) for details.



ClinicalTrials.gov is a website and online database of clinical research studies and information about their results. The National Library of Medicine (NLM) maintains the website. **The study sponsor or investigator submits information** about their study to ClinicalTrials.gov and **is responsible for the safety, science, and accuracy** of any study they list.

Before joining a study, talk to your health care professional about possible risks and benefits. To learn more about taking part in studies, read [Learn About Studies](#).

Completed ⓘ

A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)

ClinicalTrials.gov ID ⓘ NCT02759107

Sponsor ⓘ Eli Lilly and Company

Information provided by ⓘ Eli Lilly and Company (Responsible Party)

Last Update Posted ⓘ 2024-01-16

[Download](#)

[Save](#)

[+ Expand all content](#)

[— Collapse all content](#)

Study Details

Researcher View

Results Posted

Record History

On this page

| Study Overview

[Contacts and Locations](#)

[Participation Criteria](#)

[Study Plan](#)

[Collaborators and Investigators](#)

[Publications](#)

[Study Record Dates](#)

[More Information](#)

Study Overview

Brief Summary

The main purposes of this study are to determine:

- The safety of tirzepatide and any side effects that might be associated with it.
- How much tirzepatide gets into the bloodstream and how long it takes the body to get rid of it.
- How tirzepatide affects the levels of blood sugar.

This study includes 3 parts (A, B and C). Part A involves a single dose of tirzepatide taken as a subcutaneous (SC) injection just under the skin and will be approximately 10 weeks in duration, including screening. Parts B and C involve 4 doses of tirzepatide taken once weekly (over 4 weeks) as a SC injection just under the skin and is approximately 12-14 weeks in duration, including screening. Each participant will enroll in only one part.

Study Start (Actual) ⓘ

2016-05-11

Primary Completion (Actual) ⓘ

2017-06-26

Study Completion (Actual) ⓘ

2017-06-26

Enrollment (Actual) ⓘ

142

Study Type ⓘ

Interventional

Eli Lilly & Co.
Exhibit 2009
BPI Labs v. Eli Lilly
IPR2025-01346
 Ex. 2009-001

Feedback

This study includes 3 parts (A, B and C). Part A involves a single dose of tirzepatide taken as a subcutaneous (SC) injection just under the skin and will be approximately 10 weeks in duration, including screening. Parts B and C involve 4 doses of tirzepatide taken once weekly (over 4 weeks) as a SC injection just under the skin and is approximately 12-14 weeks in duration, including screening. Each participant will enroll in only one part.

This study is for research purposes only, and is not intended to treat any medical condition.

Official Title

A Single- and Multiple-Ascending Dose Study in Healthy Subjects to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3298176 and Multiple Doses in Patients With Type 2 Diabetes Mellitus

Conditions

- Healthy
- Type 2 Diabetes Mellitus (T2DM)

Intervention / Treatment

- Drug: Tirzepatide
- Drug: Placebo
- Drug: Dulaglutide

Other Study ID Numbers

- 16119
- I8F-MC-GPGA (Other Identifier) (OTHER: Eli Lilly and Company)

2017-06-26

Enrollment (Actual)

142

Study Type

Interventional

Phase

Phase 1

Resource links provided by the National Library of Medicine



MedlinePlus Genetics related topics: Type 2 diabetes

Drug Information available for: Dulaglutide Tirzepatide

FDA Drug and Device Resources

Contacts and Locations

This section provides contact details for people who can answer questions about joining this study, and information on where this study is taking place.

To learn more, please see the [Contacts and Locations section in How to Read a Study Record](#).

This study has 2 locations

United States

Florida Locations

- South Miami, Florida, United States, 33143
Miami Research Associates

Singapore

- Singapore, Singapore, 117597
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.




Ex. 2009-002

This study has 2 locations

Singapore

 **Singapore, Singapore, 117597**

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.



[Click to view interactive map](#)

Participation Criteria

Researchers look for people who fit a certain description, called [eligibility criteria](#). Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read [Learn About Studies](#).

Eligibility Criteria	
<div><div>Description</div><div><div>Inclusion Criteria:</div><div><ul style="list-style-type: none">Healthy participants (Parts A and B) and participants with T2DM diagnosed at least 1 year before enrollment (Part C)Have a screening body mass index (BMI) of greater than 18.5 and less than or equal to 40.0 kilograms per meter squared (kg/m²), inclusiveParticipants with T2DM (Part C only): have T2DM controlled with diet and exercise alone or are stable on a single oral antidiabetic medication (metformin for at least 30 days or sulfonylureas). Participants receiving sulfonylureas may participate only if this treatment is stopped for at least 6 weeks before dosing with study drug</div></div><div><div>Exclusion Criteria:</div><div><ul style="list-style-type: none">Have known allergies to tirzepatide, glucagon-like peptide (GLP)-1 analogs, or related compoundsHave an abnormality in the 12-lead electrocardiogram (ECG) at screening that, in the opinion of the investigator, increases the risks associated with participating in the studyHave a history or presence of pancreatitis (history of chronic pancreatitis or idiopathic acute pancreatitis), elevation in serum amylase or lipase (greater than 2-fold the upper limit of normal [ULN]) or gastrointestinal (GI) disorder (for example, relevant esophageal reflux or gall bladder disease) or any GI disease which impacts gastric emptying (for example, gastric bypass surgery, pyloric stenosis, with the exception of appendectomy) or could be aggravated by glucagon-like peptide-1 (GLP-1) analogs or dipeptidyl peptidase (DPP)-IV inhibitors</div></div><div><div>Participants with T2DM (Part C only)</div><div><ul style="list-style-type: none">Have had more than 1 episode of severe hypoglycemia, as defined by the American Diabetes Association criteria, within 6 months before entry into the study or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms</div></div><div><div>All Study Participants (Parts B and C only)</div><div><ul style="list-style-type: none">have known allergies to tirzepatide, GLP-1 analogs, or related compounds, or acetaminophen</div></div></div>	<div><div>Ages Eligible for Study ⓘ</div><div>21 Years to 70 Years (Adult, Older Adult)</div></div> <div><div>Sexes Eligible for Study ⓘ</div><div>All</div></div> <div><div>Accepts Healthy Volunteers ⓘ</div><div>Yes</div></div>

- hypoglycemic symptoms
- All Study Participants (Parts B and C only)
- have known allergies to tirzepatide, GLP-1 analogs, or related compounds, or acetaminophen

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

[Expand all](#) / [Collapse all](#)

How is the study designed?

Design Details

Primary Purpose ⓘ : Basic Science

Allocation ⓘ : Randomized

Interventional Model ⓘ : Parallel Assignment

Masking ⓘ : Double (Participant, Investigator)

Arms and Interventions

Participant Group/Arm ⓘ	Intervention/Treatment ⓘ
Experimental: Tirzepatide (Part A) Participants received escalating single doses of either 0.25 milligram (mg) or 0.5mg or 1mg, or 2.5mg or 5mg or 8mg Tirzepatide by subcutaneous injection.	Drug: Tirzepatide <ul style="list-style-type: none">Administered SCOther Names:<ul style="list-style-type: none">LY3298176
Placebo Comparator: Placebo (Part A) Participants received single dose of placebo by subcutaneous injection.	Drug: Placebo <ul style="list-style-type: none">Administered SC
Experimental: Tirzepatide (Part B) Participants received fixed doses of either 0.5mg or 1.5mg or 4.5mg Tirzepatide once weekly for four weeks or titrated doses of 5mg, 5mg, 8mg and 10mg Tirzepatide once weekly for four weeks by subcutaneous injection.	Drug: Tirzepatide <ul style="list-style-type: none">Administered SCOther Names:<ul style="list-style-type: none">LY3298176
Placebo Comparator: Placebo (Part B) Participants received placebo once weekly for four weeks by subcutaneous injection.	Drug: Placebo <ul style="list-style-type: none">Administered SC
Active Comparator: Dulaglutide	Drug: Dulaglutide

B) Participants received placebo once weekly for four weeks by subcutaneous injection.	<ul style="list-style-type: none">Administered SC
Active Comparator: Dulaglutide (Part B) Participants received 1.5mg Dulaglutide once weekly for four weeks by subcutaneous injection.	Drug: Dulaglutide <ul style="list-style-type: none">Administered SCOther Names:<ul style="list-style-type: none">Trulicity®
Experimental: Tirzepatide (Part C) Participants received fixed doses of either 0.5mg or 5mg Tirzepatide once weekly for four weeks or titrated doses of 5mg,5mg,10mg,10mg or 5mg,5mg,10mg,15mg Tirzepatide once weekly for four weeks by subcutaneous injection	Drug: Tirzepatide <ul style="list-style-type: none">Administered SCOther Names:<ul style="list-style-type: none">LY3298176
Placebo Comparator: Placebo (Part C) Participants received placebo once weekly for four weeks by subcutaneous injection.	Drug: Placebo <ul style="list-style-type: none">Administered SC

What is the study measuring?

Primary Outcome Measures ⓘ		
Outcome Measure	Measure Description	Time Frame
Number of Participants With One or More Serious Adverse Event(s) (SAEs)	Number of participants with one or more SAEs considered by the investigator to be related to study drug administration. A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, were reported in the Reported Adverse Events module	Baseline through Day 43 (Part A) and Day 57 (Part B and C)
Secondary Outcome Measures ⓘ		
Outcome Measure	Measure Description	Time Frame
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide in Part A.	Area under the concentration versus time curve from zero to infinity (AUC [0-∞]) of Tirzepatide in Part A.	Predose, 8hours(h), 24h,48h,72h, 96h,120h,168 h,336h postdose, day 29, day 43
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide in Part A.	Area under the concentration versus time curve during 1 dose	Predose

Time Curve (AUC) of Tirzepatide in Part A.		96h,120h,168 h,336h postdose, day 29, day 43
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide in Part B	Area under the concentration versus time curve during 1 dosing interval (AUC [0-τ]) of Tirzepatide in Part B. τ equals 168 hours.	Predose, 8hours(h), 24h,48h,72h, 168h postdose
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide in Part C	Area under the concentration versus time curve during 1 dosing interval (AUC [0-τ]) of Tirzepatide in Part C. τ equals 168 hours.	Predose, 8hours(h), 24h,48h,72h, 168h postdose
Pharmacodynamics (PD): Ratio of AUC of Glucose on Day 2 to Baseline (Part C)	PD: Glucose area under the concentration versus time curve from time 0 to 2 hours (AUC[0-2h]) in Part C. Ratio to Baseline (Day -1) AUC (0-2h).	Pre-glucose dose, 0.5, 1, 1.5, 2 hours post-glucose dose on Day -1 and Day 2
Pharmacodynamics (PD): Ratio of AUC of Glucose on Day 23 to Baseline (Part C)	PD: Glucose area under the concentration versus time curve from time 0 to 2 hours (AUC[0-2h]) in Part C. Ratio to Baseline (Day -1) AUC (0-2h).	Pre-glucose dose, 0.5, 1, 1.5, 2 hours post-glucose dose on Day -1 and Day 23

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor ⓘ

Eli Lilly and Company

Investigators ⓘ

- Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company

Publications

From PubMed

These publications come from PubMed, a public database of scientific and medical articles. This list is automatically created by ClinicalTrials.gov Identifier (NCT Number), and these articles may or may not be about the study.

- [Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, D'Alessio DA, Haupt A. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018 Dec;18:3-14. doi: 10.1016/j.molmet.2018.09.009. Epub 2018 Oct 3. !\[\]\(a12c24f076b00b9566e5c8bd18cfc66d_img.jpg\)](#)

On this page
Study Overview
Contacts and Locations
Participation Criteria
Study Plan
Collaborators and Investigators
Publications
Study Record Dates
More Information

These publications come from PubMed, a public database of scientific and medical articles. This list is automatically created by ClinicalTrials.gov Identifier (NCT Number), and these articles may or may not be about the study.

- [Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, D'Alessio DA, Haupt A. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018 Dec;18:3-14. doi: 10.1016/j.molmet.2018.09.009. Epub 2018 Oct 3. ↗](#)

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
<div>First Submitted ⓘ 2016-04-29</div> <div>First Submitted that Met QC Criteria ⓘ 2016-04-29</div> <div>First Posted (Estimated) ⓘ 2016-05-03</div>	<div>Results First Submitted ⓘ 2022-06-09</div> <div>Results First Submitted that Met QC Criteria ⓘ 2023-04-17</div> <div>Results First Posted ⓘ 2024-01-16</div>	<div>Last Update Submitted that met QC Criteria ⓘ 2023-04-17</div> <div>Last Update Posted ⓘ 2024-01-16</div> <div>Last Verified ⓘ 2023-04</div>

More Information

Record History

[Expand all](#) / [Collapse all](#)

Terms related to this study

Additional Relevant MeSH Terms

Glucose Metabolism Disorders

Metabolic Diseases

Endocrine System Diseases

Diabetes Mellitus

Diabetes Mellitus, Type 2

Incretins

Hormones

Hormones, Hormone Substitutes, and Hormone Antagonists

Physiological Effects of Drugs

Glucagon-Like Peptide-1 Receptor Agonists

Hypoglycemic Agents

Dulaglutide

Tirzepatide

Plan for Individual Participant Data (IPD)

Plan to Share Individual Participant Data (IPD)?

Ex. 2009-007

On this page

Study Overview

Contacts and Locations

Participation Criteria

Study Plan

Collaborators and Investigators

Publications

Study Record Dates

More Information

Tirzepatide

Plan for Individual Participant Data (IPD)

Plan to Share Individual Participant Data (IPD)?

Yes

IPD Plan Description

Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

IPD Sharing Time Frame

Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

IPD Sharing Url

<http://vivli.org/>

IPD Sharing Access Criteria

A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

IPD Sharing Supporting Information Type

Study Protocol
Statistical Analysis Plan (SAP)
Clinical Study Report (CSR)

Drug and device information, study documents, and helpful links

Study Documents 1 Provided by Eli Lilly and Company

- [Study Protocol](#) [PDF, 0.72MB, 2017-02-06]
- [Statistical Analysis Plan](#) [PDF, 0.43MB, 2016-05-04]

Helpful Links Provided by Eli Lilly and Company

[Click here for more information about this study:A Study of tirzepatide in Participants With Type 2 Diabetes \(T2DM\)](#)

About

[About ClinicalTrials.gov](#)

[Release Notes](#)

[Site Map](#)

Help

[Give us feedback](#)

[Glossary](#)

[Customer Support](#)

Legal

[Disclaimer](#)

[Terms and Conditions](#)

Clinical Trials.gov

National Library of Medicine
8600 Rockville Pike, Bethesda, MD
20894

National Library of Medicine
National Center for Biotechnology Information

ClinicalTrials.gov

An official website of the [U.S. Department of Health and Human Services](#), [National Institutes of Health](#), [National Library of Medicine](#), and [National Center for Biotechnology Information](#).

[About HHS](#)

[About NCBI](#)

[About NIH](#)

[About NLM](#)

[Accessibility support](#)

[FOIA requests](#)

[No FEAR Act data](#)

[Office of the Inspector General](#)

[Privacy policy](#)

[HHS Vulnerability Disclosure](#)

Looking for U.S. government information and services? [Visit USA.gov](#)

→ Back to Top

Feedback

Ex. 2009-008

Document title: Study Details | A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM) | ClinicalTrials.gov

Capture URL: <https://clinicaltrials.gov/study/NCT02759107>

Capture timestamp (UTC): Fri, 08 Aug 2025 06:59:32 GMT

Page 8 of 9

On this page
Study Overview
Contacts and Locations
Participation Criteria
Study Plan
Collaborators and Investigators
Publications
Study Record Dates
More Information

Plan for Individual Participant Data (IPD)

Plan to Share Individual Participant Data (IPD)?

Yes

IPD Plan Description

Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

IPD Sharing Time Frame

Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

IPD Sharing Url

<http://vivli.org/>

IPD Sharing Access Criteria

A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

IPD Sharing Supporting Information Type

Study Protocol
Statistical Analysis Plan (SAP)
Clinical Study Report (CSR)

Drug and device information, study documents, and helpful links

Study Documents 1 Provided by Eli Lilly and Company

- [Study Protocol](#) [PDF, 0.72MB, 2017-02-06]
- [Statistical Analysis Plan](#) [PDF, 0.43MB, 2016-05-04]

Helpful Links Provided by Eli Lilly and Company

[Click here for more information about this study:A Study of tirzepatide in Participants With Type 2 Diabetes \(T2DM\)](#)

About

- [About ClinicalTrials.gov](#)
- [Release Notes](#)
- [Site Map](#)

Help

- [Give us feedback](#)
- [Glossary](#)
- [Customer Support](#)

Legal

- [Disclaimer](#)
- [Terms and Conditions](#)

Clinical Trials.gov

National Library of Medicine
8600 Rockville Pike, Bethesda, MD
20894



- | | | | |
|---------------------------|---------------------------------------|---|--|
| About HHS | About NCBI | No FEAR Act data | HHS Vulnerability Disclosure |
| About NIH | Accessibility support | Office of the Inspector General | |
| About NLM | FOIA requests | Privacy policy | |

Looking for U.S. government information and services? [Visit USA.gov](#)

Revision: v2.16.11

[HHS Vulnerability Disclosure](#)

→ Back to Top

Feedback